Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 1 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

0
Player Avatar biotiempo (55.02) Submitted: 4/4/2007 10:18:26 AM : Outperform Start Price: $4.91 PCYC Score: +571.14

After the Dendreon panel recommendation, Pharmacyclics made a filing with the FDA that among other things seeks a review of Xcytrin by an outside panel of experts. This coupled with lung cancer advocacy group involvement increases the chances of a favorable outcome regarding FDA approval.

Featured Broker Partners


Advertisement